Table 5.
Presentation of Cerebral Cortex Hemisphere Tissue NFκB and MDA Concerning the Effect of 2 Weeks (0.9mg/kg) Intranasal Administration of Treatment in Different Experimental Groups
| Groups | NFκB (ng/mg) | MDA (n.mol/mg) |
|---|---|---|
| Normal control | 1.62 ± 0.12 | 0.84 ± 0.02 |
| Positive control | 6.83± 0.37a | 5.07± 0.10a |
| CIT solution | 6.06± 0.08b,f | 4.13 ± 0.12a,b,e,f,g |
| Control thermogel | 5.08± 0.05a,b,f | 3.66± 0.08a,d,e,f |
| CIT-TBLs thermogel | 4.42 ± 0.27a,b,f | 2.95 ± 0.10a,b,d,c,e,f |
| CIT-HA*TBLs thermogel | 2.00± 0.00ac,d,e,g | 0.99± 0.01b,d,c,e,f,g |
| HA*TBLs thermogel | 4.38± 0.33a,b,f | 3.20± 0.05b,d,g |
Notes: AD: Alzheimer’s the mean of 6–8 values ± standard error of the mean (S.E.M). aSignificantly different from the normal control group, bSignificantly different from the positive control group, cCIT solution group; dControl thermogel; eCIT-TBLs thermogel; fCIT-HA*TBLs thermo gel; gHA*TBLs thermogel group at p < 0.05.